Grants and Contributions:
Title:
RNA therapeutic using nanoparticle-based platform
Agreement Number:
995465
Agreement Value:
$183,500.00
Agreement Date:
Sep 1, 2022 - Sep 30, 2023
Description:
QurCan Therapeutics is developing the next generation RNA therapeutics using its proprietary BBB-crossing nanoparticle platform technology to overcome the treatment-resistance in brain tumors.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5G 1M1
Reference Number:
172-2022-2023-Q2-995465
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
751921719
Recipient Type:
For-profit organization
Recipient's Legal Name:
QurCan Therapeutics Inc.
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254